164 related articles for article (PubMed ID: 23010947)
1. TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning.
Packard AE; Leung PY; Vartanian KB; Stevens SL; Bahjat FR; Stenzel-Poore MP
J Cereb Blood Flow Metab; 2012 Dec; 32(12):2193-200. PubMed ID: 23010947
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 9: a new target of ischemic preconditioning in the brain.
Stevens SL; Ciesielski TM; Marsh BJ; Yang T; Homen DS; Boule JL; Lessov NS; Simon RP; Stenzel-Poore MP
J Cereb Blood Flow Metab; 2008 May; 28(5):1040-7. PubMed ID: 18183029
[TBL] [Abstract][Full Text] [Related]
3. Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor-Alpha Production in Mice after Bone Marrow Transplantation.
Liu J; Guo YM; Onai N; Ohyagi H; Hirokawa M; Takahashi N; Tagawa H; Ubukawa K; Kobayashi I; Tezuka H; Minamiya Y; Ohteki T; Sawada K
Biol Blood Marrow Transplant; 2016 Apr; 22(4):627-636. PubMed ID: 26740374
[TBL] [Abstract][Full Text] [Related]
4. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
Assaf A; Esteves H; Curnow SJ; Browning MJ
Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemia-reperfusion injury.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Ohshima K; Horiuchi M
Hypertension; 2011 Sep; 58(3):404-9. PubMed ID: 21768524
[TBL] [Abstract][Full Text] [Related]
6. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism.
Leung PY; Stevens SL; Packard AE; Lessov NS; Yang T; Conrad VK; van den Dungen NN; Simon RP; Stenzel-Poore MP
Stroke; 2012 May; 43(5):1383-9. PubMed ID: 22403050
[TBL] [Abstract][Full Text] [Related]
8. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo.
Knuefermann P; Baumgarten G; Koch A; Schwederski M; Velten M; Ehrentraut H; Mersmann J; Meyer R; Hoeft A; Zacharowski K; Grohé C
Respir Res; 2007 Oct; 8(1):72. PubMed ID: 17925007
[TBL] [Abstract][Full Text] [Related]
9. Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.
Ramaprakash H; Hogaboam CM
Int Arch Allergy Immunol; 2010; 152(2):98-112. PubMed ID: 20016192
[TBL] [Abstract][Full Text] [Related]
10. Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance.
Rosenzweig HL; Minami M; Lessov NS; Coste SC; Stevens SL; Henshall DC; Meller R; Simon RP; Stenzel-Poore MP
J Cereb Blood Flow Metab; 2007 Oct; 27(10):1663-74. PubMed ID: 17327883
[TBL] [Abstract][Full Text] [Related]
11. CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.
Campbell JD; Cho Y; Foster ML; Kanzler H; Kachura MA; Lum JA; Ratcliffe MJ; Sathe A; Leishman AJ; Bahl A; McHale M; Coffman RL; Hessel EM
J Clin Invest; 2009 Sep; 119(9):2564-76. PubMed ID: 19726873
[TBL] [Abstract][Full Text] [Related]
12. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
13. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
14. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
15. Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands.
Rumio C; Sommariva M; Sfondrini L; Palazzo M; Morelli D; Viganò L; De Cecco L; Tagliabue E; Balsari A
J Cell Physiol; 2012 Mar; 227(3):1107-13. PubMed ID: 21567398
[TBL] [Abstract][Full Text] [Related]
16. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
17. Cytidine-phosphate-guanosine oligodeoxynucleotides in combination with CD40 ligand decrease periodontal inflammation and alveolar bone loss in a TLR9-independent manner.
Zhao Q; Hu Y; Deng S; Yu P; Chen B; Wang Z; Han X
J Appl Oral Sci; 2018; 26():e20170451. PubMed ID: 29791566
[TBL] [Abstract][Full Text] [Related]
18. The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice.
Zhou Y; Pan J; Peng Q; Dong Z; Deng L; Wang Y
CNS Neurol Disord Drug Targets; 2017; 16(5):624-633. PubMed ID: 28176622
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
20. Involvement of DNA-PKcs in the type I IFN response to CpG-ODNs in conventional dendritic cells in TLR9-dependent or -independent manners.
Ma C; Spies NP; Gong T; Jones CX; Chu WM
PLoS One; 2015; 10(3):e0121371. PubMed ID: 25812014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
